A Study to Investigate LYL797 in Adults With Solid Tumors
Public ClinicalTrials.gov record NCT05274451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer (Ovarian cancer), or Endometrial cancer. The first part of the study will determine the safe dose for the next part of the study, and will enroll patients with TNBC, NSCLC, Ovarian or Endometrial cancer. The second part of the study will test that dose in additional patients with TNBC, NSCLC, Ovarian or Endometrial cancer.
Study identification
- NCT ID
- NCT05274451
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 57 participants
Conditions and interventions
Conditions
- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Advanced Breast Cancer
- Advanced Lung Carcinoma
- NSCLC
- NSCLC, Recurrent
- NSCLC Stage IV
- Relapsed Cancer
- Relapse/Recurrence
- Recurrent Breast Cancer
- Recurrent NSCLC
- Platinum-resistant Ovarian Cancer
- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Endometrioid Tumor
- High Grade Serous Carcinoma
- Ovarian Epithelial Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2022
- Primary completion
- Nov 26, 2024
- Completion
- Nov 26, 2024
- Last update posted
- Jun 30, 2025
2022 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| University of California, Los Angeles | Santa Monica | California | 90404 | — |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| University of Miami | Miami | Florida | 33136 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health and Science University Hospital | Portland | Oregon | 97239 | — |
| Sidney Kimmel Cancer Center, Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Sarah Cannon Research Institute and Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Froedtert Hospital, Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Non-small Cell Lung Cancer trials
Other public records listing Non-small Cell Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07806773: Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer Not yet recruiting
- NCT06568939: A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting
- NCT04035486: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) Active, not recruiting
- NCT05245500: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion Recruiting
- NCT07250477: Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer Recruiting
- NCT07777822: Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05274451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2025 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05274451 live on ClinicalTrials.gov.